Alexandre Rozenholc
Papers
1
Total Citations
84
H-Index
1
About
Alexandre Rozenholc is a leading figure in gynecologic oncology, with a focused expertise in sentinel lymph node mapping for endometrial cancer. His most impactful work, a 2019 randomized controlled trial comparing indocyanine green (ICG) to methylene blue, has garnered 84 citations and fundamentally shifted clinical practice. By demonstrating the superior detection rates of ICG, Rozenholc provided robust evidence for adopting near-infrared fluorescence imaging as the standard of care, enhancing surgical precision and reducing patient morbidity. This landmark study not only validated a novel technique but also set a new benchmark for minimally invasive staging in endometrial cancer. Beyond this trial, his research continues to refine oncologic surgical protocols, emphasizing evidence-based innovation to improve outcomes. With his work cited by peers worldwide, Rozenholc’s contributions have solidified his reputation as a clinician-scientist dedicated to translating rigorous data into tangible advances in women’s cancer care.
Research Focus
Key Achievements
Top Papers
- 1